Your search returned 22 results. Subscribe to this search

Not what you expected? Check for suggestions
|
1. 432P QTWiST analysis to compare the benefit of maintenance Erlotinib versus pemetrexed patients with EGFR non mutated NSCLC

by Turkar S [Corresponding author] | Joshi A | Noronha V | Patil V | Sharma M | Vora S | More S | Goud S | Prabhash K.

In Annals of Oncology
Material type: article Article; Format: print Publisher: 2017Availability: Items available for loan: Tata Memorial Hospital (1).

2. Efficacy of gefitinib in epidermal growth factor receptor-activating mutation-positive nonsmall cell lung cancer: Does exon 19 deletion differ from exon 21 mutation?

by Joshi A | Joshi A | Patil V | Noronha V | Chougule A | Bhattacharjee A | Kumar R | Goud S | More S | Ramaswamy A | Karpe A | Pande N | Chandrasekharan A | Goel A | Talreja V | Mahajan A | Janu A | Purandare N | Prabhash K [Corresponding author].

In Lung India
Material type: article Article; Format: print Publisher: 2018Availability: Items available for loan: Tata Memorial Hospital (1).

3. Efficacy of Gefitinib in Epidermal Growth Factor Receptor-Activating Mutation-Positive Nonsmall Cell Lung Cancer: Does Exon 19 Deletion Differ from Exon 21 Mutation?

by Joshi A | Patil V | Noronha V | Chougule A | Bhattacharjee A | Kumar R | Goud S | More S | Ramaswamy A | Karpe A | Pande N | Chandrasekharan A | Goel A | Talreja V | Mahajan A | Janu A | Purandare N | Prabhash K [Corresponding Author].

In Lung India
Material type: article Article; Format: print Publisher: 2017Availability: Items available for loan: Tata Memorial Hospital (1).

4. Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?

by Joshi A | Noronha V | Patil VM | Chougule A | Bhattacharjee A | Kumar R | Goud S | More S | Ramaswamy A | Karpe A | Pande N | Chandrasekharan A | Goel A | Talreja V | Mahajan A | Janu A | Purandare N | Prabhash K.

In Chemotherapy Research and Practice
Material type: article Article; Format: print Publisher: 2017Availability: Items available for loan: Tata Memorial Hospital (1).

5. Impact of exon 19 versus exon 21 EGFR-activating mutation on outcomes with upfront pemetrexed–carboplatin chemotherapy

by Noronha V | Patil V | Joshi A | Chougule A | Bhattacharjee A | Kumar R | More S | Goud S | Karpe A | Ramaswamy A | Pande N | Chandrasekharan A | Goel A | Talreja V | Mahajan A | Janu A | Purandare N | Prabhash K.

In Ecancermedicalscience
Material type: article Article; Format: print Publisher: 2017Availability: Items available for loan: Tata Memorial Hospital (1).

6. LBA10 - A randomized investigator initiated phase III study comparing low dose gemcitabine to standard dose gemcitabine with platinum in advanced squamous non driver mutated non-small cell lung cancer

by Chandrashekharan A | Patil V | Noronha V | Joshi A | Choughle A | Punatar S | Mahajan A | Janu A | Purandare N | Goud S | More S | Das S | Agrawal A | Rajourohit A | Majumdar S | Khaddar S | Prabhash K.

In Annals of Oncology
Material type: article Article; Format: print Publisher: 2018Availability: Items available for loan: Tata Memorial Hospital (1).

7. P2.01-102 Outcome of Patients with EGFR Exon 19 Mutation in a Phase III Randomized Trial Comparing Gefitinib to Gefitinib with Chemotherapy

by Prabhash K | Noronha V | Patil V | Joshi A | Chougule A | Mahajan A | Janu A | Kumar R | More S | Goud S | Kumar N | Daware N | Bhattacherjee A | Shah S | Yadav A | Banavali S.

In Journal of Thoracic Oncology
Material type: article Article; Format: print Publisher: 2019Availability: Items available for loan: Tata Memorial Hospital (1).

8. P3.02b-007 Differential Efficacy of Gefitinib in Exon 19 or Exon 21 Mutated Adenocarcinoma Lung

by Goel A | Joshi A | Patil V | Noronha V | Chougule A | Mahajan A | Janu A | Kaushal R | Goud S | More S | Karpe A | Ramaswamy A | Pande N | Chandrasekharan A | Talreja V | Chanana R | Prabhash K.

In Journal of Thoracic Oncology
Material type: article Article; Format: print Publisher: 2017Availability: Items available for loan: Tata Memorial Hospital (1).

9. P3.02b-055 Impact of pemetrexed chemotherapy in exon 19 or exon 21 mutated nsclc

by Talreja V | Noronha V | Patil V | Joshi A | Chougule A | Mahajan A | Janu A | Goud S | More S | Karpe A | Ramaswamy A | Pande N | Chandrasekharan A | Goel A | Prabhash K.

In Journal of Thoracic Oncology
Material type: article Article; Format: print Publisher: New York, NY : Elsevier 2017Online access: PDF Availability: Items available for loan: Tata Memorial Hospital (1).

10. P3.02b-058 Second-Line Therapy in EGFR Activating Mutation Positive Advanced NSCLC: Analysis from a Randomized Phase III First-Line Trial

by Ramaswamy A | Patil V | Joshi A | Noronha V | Choughule A | Mahajan A | Goud S | More S | Karpe A | Pande N | Chandrasekharan A | Goel A | Talreja V | Prabhash K.

In Journal of Thoracic Oncology
Material type: article Article; Format: print Publisher: 2017Availability: Items available for loan: Tata Memorial Hospital (1).

11. P3.02b-090 Pemetrexed versus gefitinib in egfr mutation positive lung cancer: results of a phase 3 study from India

by Kumar Prabhash | Patil V | Joshi A | Noronha V | Chougule A | Mahajan A | Janu A | Goud S | More S | Kaushal R | Karpe A | Ramaswamy A | Pande N | Talreja V.

In Journal of Thoracic Oncology
Material type: article Article; Format: print Publisher: New York, NY : Elsevier 2017Online access: PDF Availability: Items available for loan: Tata Memorial Hospital (1).

12. Phase III Non-inferiority Study Evaluating Efficacy and Safety of Low Dose Gemcitabine Compared to Standard Dose Gemcitabine With Platinum in Advanced Squamous Lung Cancer

by Patil V | Noronha V | Joshi V | Chougule A | Kannan S | Bhattacharjee A | Goud S | More S | Chandrasekharan A | Menon N | Srinivas S | Vallathol DH | Dsouza H | Majumdar S | Das S | Zawar A | Khaddar S | Kumar A | Singh G | Aditya K | Kumar P [Corresponding Author] | Ravind R | Trivedi V | Bahel V | Mahajan A | Janu A | Purandare N | Kumar P [Corresponding Author].

In EClinicalMedicine
Material type: article Article; Format: print Publisher: 2019Availability: Items available for loan: Tata Memorial Hospital (1).

13. Phase III randomized trial comparing intravenous to oral iron in patients with cancer-related iron deficiency anemia not on erythropoiesis stimulating agents

by Noronha V | Joshi A | Patil VM | Banavali SD | Gupta S | Parikh PM | Marfatia S | Punatar S | More S | Goud S | Nakti D | Prabhash K.

In Asia-Pacific Journal of Clinical Oncology
Material type: article Article; Format: print Publisher: 2018Availability: Items available for loan: Tata Memorial Hospital (1).

14. Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma

by Patil VM | Noronha V | Joshi A | Choughule AB | Bhattacharjee A | Kumar R | Goud S | More S | Ramaswamy A | Karpe A | Pande N | Chandrasekharan A | Goel A | Talreja V | Mahajan A | Janu A | Purandare N | Prabhash K [Corresponding author].

In ESMO Open
Material type: article Article; Format: print Publisher: 2017Availability: Items available for loan: Tata Memorial Hospital (1).

15. PUB118 Pre-chemotherapy EGFR mutation status & outcomes with second line gefitinib in advanced adenocarcinoma lung

by Karpe A | Noronha V | Patil V | Joshi A | Chougule A | Janu A | More S | Goud S | Ramaswamy A | Pande N | Chandrasekharan A | Goel A | Talreja V | Prabhash K.

In Journal of Thoracic Oncology
Material type: article Article; Format: print Publisher: New York: Elsevier 2017Online access: PDF Availability: Items available for loan: Tata Memorial Hospital (1).

16. A randomized clinical trial evaluating the efficacy and safety of the addition of oral metronomic chemotherapy after completion of standard chemoradiation versus observation in patients with locally advanced esophageal and gastroesophageal junction squamous cell carcinoma.

by Noronha V | Patil VM | Joshi A | Menon NS | Goud S | More S | Nakt D | Yadav A | Shah S | Mahajan A | Janu A | Kumar R | Kannan S | Agarwa JP | Tibdewal A | Mummudi N | Banavali SD [Corresponding Author] | Kumar Prabhash K.

In Journal of Clinical Oncology
Material type: article Article; Format: print Publisher: 2021 Availability: Items available for loan: Tata Memorial Hospital (1).

17. Randomized phase 3 open label study of quality of life of patients on Pemetrexed versus Erlotinib as maintenance therapy for advanced non squamous non EGFR mutated non small cell lung cancer.

by Patil V | Joshi A | Noronha V | Kanan S | Agarwala V | Chougule A | Bhattacharjee A | Chandrasekharan A | Pande N | Simha V | Goud S | More S | Kumar R | Mahajan A | Janu A | Purandare N | Prabhash K [Corresponding Author].

In Oncotarget
Material type: article Article; Format: print Publisher: 2019Availability: Items available for loan: Tata Memorial Hospital (1).

18. Reasons for Initiation of Areca Nut and Related Products in Patients with Oral Submucous Fibrosis within an Endemic Area in Gujarat, India

by More CB | Rao NR [Corresponding Author ] | More S | Johnson NW.

In Substance Use & Misuse
Material type: article Article; Format: print Publisher: 2020Availability: Items available for loan: Tata Memorial Hospital (1).

19. Repeat biopsy in epidermal growth factor receptor mutation-positive nonsmall cell lung cancer: Feasibility, limitations, and clinical utility in Indian patients

by Zanwar S | Noronha V | Joshi A | Patil VM | Chougule A | Kumar R | More S | Goud S | Janu A | Mahajan A | Prabhash K [Corresponding author].

In Indian Journal of Cancer
Material type: article Article; Format: print Publisher: 2017Availability: Items available for loan: Tata Memorial Hospital (1).

20. Retroperitoneal Mass-lymphangiomyoma

by More S | Patil PP | Phanasopakar M | Kulkarni SH | mdhurakilledar@gmail.com | Killedar MM.

In Indian Journal of Surgery
Material type: article Article; Format: print Publisher: 2012Online access: Click here to access online Availability: Items available for loan: Tata Memorial Hospital [Call number: ] (1).

Powered by Koha